Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1
Chandrakanth Reddy Edamakanti, … , Marco Martina, Puneet Opal
Chandrakanth Reddy Edamakanti, … , Marco Martina, Puneet Opal
Published March 13, 2018
Citation Information: J Clin Invest. 2018;128(6):2252-2265. https://doi.org/10.1172/JCI96765.
View: Text | PDF
Research Article Neuroscience

Mutant ataxin1 disrupts cerebellar development in spinocerebellar ataxia type 1

  • Text
  • PDF
Abstract

Spinocerebellar ataxia type 1 (SCA1) is an adult-onset neurodegenerative disease caused by a polyglutamine expansion in the protein ATXN1, which is involved in transcriptional regulation. Although symptoms appear relatively late in life, primarily from cerebellar dysfunction, pathogenesis begins early, with transcriptional changes detectable as early as a week after birth in SCA1-knockin mice. Given the importance of this postnatal period for cerebellar development, we asked whether this region might be developmentally altered by mutant ATXN1. We found that expanded ATXN1 stimulates the proliferation of postnatal cerebellar stem cells in SCA1 mice. These hyperproliferating stem cells tended to differentiate into GABAergic inhibitory interneurons rather than astrocytes; this significantly increased the GABAergic inhibitory interneuron synaptic connections, disrupting cerebellar Purkinje cell function in a non–cell autonomous manner. We confirmed the increased basket cell–Purkinje cell connectivity in human SCA1 patients. Mutant ATXN1 thus alters the neural circuitry of the developing cerebellum, setting the stage for the later vulnerability of Purkinje cells to SCA1. We propose that other late-onset degenerative diseases may also be rooted in subtle developmental derailments.

Authors

Chandrakanth Reddy Edamakanti, Jeehaeh Do, Alessandro Didonna, Marco Martina, Puneet Opal

×

Figure 5

Sca1154Q/2Q cerebellar stem cells show increased proliferation and differentiation in vitro.

Options: View larger image (or click on image) Download as PowerPoint

Sca1154Q/2Q cerebellar stem cells show increased proliferation and diff...
(A) Neurospheres derived from isolated prominin-1+ cerebellar stem cells of WT mice and SCA1 littermates. Scale bar: 100 μm. (B) Neurospheres express typical stem cell markers prominin-1, nestin, and GFAP. Scale bar: 50 μm. (C) The number of neurospheres derived from prominin-1–positive SCA1 cells is greater than that from WT controls; SCA1 cells also show greater BrdU uptake. n = 4 pairs of mice. (D and E) Differentiated cerebellar stem cells stained for GABAergic. Scale bars: 50 μm (Pax2); 100 μm (glial markers GFAP). SCA1 stem cells yield a greater number of both Pax2 and GFAP cells than WT stem cells. n = 3 pairs of mice. **P < 0.01; ***P < 0.001, 2-tailed unpaired Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts